EVO News and Press, Evotec SE From 09/20/22

JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS ANTI-PLAGUE MABS EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES HAMBURG, GERMANT / ACCESSWIRE / September 20, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDA...

J.POD ® TOULOUSE, FRANCE (EU) BRINGS A DISRUPTIVE, FLEXIBLY SCALABLE BIOLOGICS MANUFACTURING TECHNOLOGY TO THE REGION THE MANUFACTURING FACILITY IS EXPECTED TO BE OPERATIONAL IN H2 2024 HAMBURG, GERMANY / ACCESSWIRE / September 16, 2-022 / Evotec SE (Frankfurt Stock Exchan...

LONDON, Ontario, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/ XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that it has completed the second and final tranche of its previously announced private ...

Evotec ( NASDAQ: EVO ) ( OTCPK:EVOTF ) is acquiring Central Glass Germany from Japanese chemical manufacturing company Central Glass Co. to expands its clinical and commercial manufacturing platform for small molecule therapeutics. Germany-based Evotec sa...

EXPANSION OF CGMP DRUG SUBSTANCE MANUFACTURING PLATFORM WILL CREATE A CLEAR PATH TO THE MARKET FOR RARE DISEASES AND PRECISION THERAPEUTICS EVOTEC GAINS A FULLY OPERATIONAL EU GMP CERTIFIED FACILITY IN HALLE/WESTPHALIA ALONG WITH A HIGHLY SKILLED TEAM OF APPROX. 60 CHEMISTS HAMBUR...

Evotec SE (EVOTF) Q2 2022 Earnings Conference Call August 11, 2022, 8:00 AM ET Company Participants Dr. Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operati...

The following slide deck was published by Evotec SE in conjunction with their 2022 Q2 earnings call. For further details see: Evotec SE 2022 Q2 - Results - Earnings Call Presentation

Evotec SE press release ( NASDAQ: EVO ): 1H Revenue of €336.9M (+24.2% Y/Y). Reported adjusted Group EBITDA totalled €33.6 m (H1 2021: €36.2 m); excellent Group gross margin increasing by 270 bps to 27.3%. Outlook for FY2022 redefine and mid...

BASE BUSINESS, NEW AND EXTENDED ALLIANCES DRIVE 24% GROWTH JUST - EVOTEC BIOLOGICS IN BUILD-UP PHASE - INVESTMENT ON TRACK ACQUISITION EXPANDS CAPABILITIES AND EXPERTISE IN CELL THERAPY GUIDANCE FOR FULL-YEAR 2022 REFINED HAMBURG, GERMANY / ACCESSWIRE / August 11, 2022 /...

Evotec ( NASDAQ: EVO ) said its Seattle-based unit Just - Evotec Biologics expanded a multi-year partnership with Alpine Immune Sciences ( NASDAQ: ALPN ) to develop a commercial process for ALPN-303. Evotec said ALPN-303 is being developed t...